MIR548AE1: A Potential Drug Target and Biomarker (G100616305)

Target Name: MIR548AE1

NCBI ID: G100616305

MIR548AE1

Other Name(s): microRNA 548ae-1 | hsa-mir-548ae-1 | hsa-miR-548ae-3p | MicroRNA 548ae-1

MIR548AE1: A Potential Drug Target and Biomarker

MIR548AE1, also known as interleukin-5 receptor alpha chain (IL-5R1), is a protein that is expressed in various tissues, including the lungs, heart, kidneys, and central nervous system. It is a member of the interleukin-5 receptor family, which is a subset of the T cell receptor family. This receptor is involved in the regulation of immune and inflammatory responses, as well as tissue repair and regeneration.

Recent studies have identified MIR548AE1 as a potential drug target in the treatment of various diseases, including asthma, eczema, and chronic obstructive pulmonary disease (COPD). MIR548AE1 has also been shown to be involved in the development and progression of chronic kidney disease, and has been identified as a potential biomarker for this disease.

The interleukin-5 receptor is a protein that is expressed in various tissues throughout the body. It is a member of the T cell receptor family, and is involved in the regulation of immune and inflammatory responses. MIR548AE1 is a specific member of this receptor family, and is expressed in the lungs, heart, kidneys, and central nervous system.

MIR548AE1 is involved in the regulation of various cellular processes that are important for immune and inflammatory responses. It has been shown to play a role in the regulation of T cell development and function, as well as the regulation of inflammation. MIR548AE1 has also been shown to be involved in the regulation of cell survival and apoptosis, as well as the regulation of angiogenesis.

In addition to its role in immune and inflammatory responses, MIR548AE1 has also been shown to be involved in the regulation of tissue repair and regeneration. This is because MIR548AE1 is involved in the regulation of cell proliferation and differentiation, as well as the regulation of cell death.

MIR548AE1 has been identified as a potential drug target in the treatment of various diseases, including asthma, eczema, and COPD. These conditions are characterized by chronic inflammation and tissue damage, and are often treated with drugs that aim to suppress these inflammatory responses. MIR548AE1 has been shown to be involved in the regulation of these inflammatory responses, and may therefore be a useful target for the treatment of these conditions.

In addition to its potential use as a drug target, MIR548AE1 has also been shown to be involved in the development and progression of chronic kidney disease. Chronic kidney disease is a condition in which the kidneys gradually lose their function over time, and can lead to a variety of serious health consequences, including kidney failure and death. MIR548AE1 has been shown to be involved in the regulation of kidney function, and has been identified as a potential biomarker for this disease.

MIR548AE1 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important for the development and maintenance of blood vessels, and is also involved in the regulation of tumor growth. MIR548AE1 has been shown to be involved in the regulation of angiogenesis, and may therefore be a useful target for the treatment of conditions that involve angiogenesis, such as cancer.

In conclusion, MIR548AE1 is a protein that is involved in the regulation of various cellular processes that are important for immune and inflammatory responses, as well as tissue repair and regeneration. It has been identified as a potential drug target for the treatment of various diseases, including asthma, eczema, and COPD, as well as chronic obstructive pulmonary disease

Protein Name: MicroRNA 548ae-1

The "MIR548AE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR548AE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets